CompletedPhase IInterventional

Phase I Trial: Quotient Code QSC303299

This is an early-stage medical study, known as a Phase I trial, with the code QSC303299. At this point, many of the specific details about what is being tested and why are not yet publicly available. This often happens with very new research to protect intellectual property or for other medical research reasons. The full information will be published within 30 months after the study has officially come to an end. This particular study is looking for male participants between 30 and 65 years old. Early-stage trials like this primarily focus on checking the safety of a new treatment and how it behaves in the body, rather than its effectiveness. We will share more information as soon as it becomes available.

At a glance

Status

Completed

Phase

Phase I

Sponsor

Vicore Pharma (Sweden)

Enrolment target

Start

07 Mar 2026

Estimated completion

22 May 2026

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

What is this study about?

This study is a Phase I clinical trial, which means it's an early step in testing a new treatment. Think of it as the very first time a new medicine or treatment is given to people. The main goal at this stage is to make sure it's safe and to understand how the body handles it, including how much of it stays in the body and for how long. It's not usually about seeing if it cures a condition, but rather if it's safe enough to study further.

At the moment, many of the specific details about this particular study, QSC303299, are not public. This is a common practice in medical research, sometimes to protect the new discovery or to allow researchers to gather all their findings first. The medical team behind the study has stated that they will share all the full details within 30 months after the trial has finished.

For now, we know that this study is looking for healthy volunteers or people with a specific condition to help test this new approach. The information we do have tells us it's specifically for men in a certain age range. As soon as more information is made public about what exactly is being tested and for which conditions, we will update this page. Your understanding and interest in supporting medical research are very valuable.

Key takeaways

This is an early-stage (Phase I) study testing a new treatment.
Full details about the study are not yet public but will be shared later.
Only men aged 30 to 65 are eligible to participate.
The main focus of a Phase I study is on safety, not effectiveness.
More information will become available once the study concludes.

Who may be eligible?

To be considered for this study, you must be a man. We are looking for men who are between 30 and 65 years old, including both of those ages.

At this time, because the full details of the study haven't been shared, we don't have specific medical conditions or other health requirements that would allow you to join or prevent you from joining.

Once the full study details are released, which will be within 30 months after the study ends, we will be able to share more precise information about who can and cannot take part.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you a man?
Are you at least 30 years old?
Are you 65 years old or younger?
Are you prepared for potential unknown risks of a new treatment?
Are you able to commit to several clinic visits, even if you don't know the full schedule yet?

Answer every question to see your result.

What does participation involve?

Because the full study details are not yet publicly available, we can't give a complete picture of what taking part would involve. However, in a typical Phase I study like this, you would generally need to attend several visits to a clinic or hospital. These visits might involve getting physical examinations, blood tests, and possibly other tests like heart scans.

You would likely receive the study treatment, which could be a medication, and the medical team would carefully monitor your health and any side effects. There would also be follow-up appointments after you've received the treatment to check on your progress and ensure your well-being. The total duration of participation varies greatly in Phase I trials, from a few days to several weeks or even months, depending on the treatment being tested. More specific information will be available once the full study details are published.

Potential risks and benefits

Participating in an early-stage study like this means you might be among the first to receive a new potential treatment, which could be seen as a benefit for some. However, the primary aim of this phase is safety, and there's no guarantee the treatment will help any specific condition. There are always potential risks with any new treatment, including unknown side effects, which could range from mild to serious. Because the full study details are not yet public, we can't list specific risks. Before joining any study, you would receive a full explanation of known risks. You always have the right to withdraw from a study at any time, for any reason, without it affecting your usual medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

Quotient Sciences Limited
City only
Nottingham, England

Common questions

What is a 'Phase I' trial?

It's the very first stage of testing a new treatment in people. The main goals are to check if it's safe and how the body handles it.

Why aren't all the study details available yet?

Sometimes, full details are kept private in early research, possibly to protect new discoveries. They will be shared later, within 30 months after the study finishes.

Who can take part in this study?

Only men between the ages of 30 and 65 are being considered for this study.

Will this treatment cure my condition?

Early-stage studies like this usually focus on safety, not on whether the treatment cures a condition. It's too early to tell if it would be effective.

How long will I need to be in the study if I join?

The exact duration isn't available yet, but Phase I trials can last from a few days to several months, with various check-up appointments.

How to find out more

Vicore Study Doctor

karin.eklund.vanderpol@vicorepharma.com +46 (0)317880560 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.